Trial Profile
A Phase IIa, Open-Label, Dose-Escalating Study to Evaluate the Safety of AV-951 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2012
Price :
$35
*
At a glance
- Drugs Tivozanib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 02 Jun 2011 New trial record